Clearmind Medicine ( NASDAQ: CMND ) has announced advancement in its proprietary MEAI-based alcohol substitute beverage program. The Co. previously announced the initiation of the last pre-clinical study required for a novel-food application submission, in accordance with novel foods and food additives legislation and regulations accepted in many jurisdictions worldwide.
According to a report, the leader in global beverage alcohol data and insights, no- and low-alcohol consumption across the world’s leading 10 no/low markets, which account for approximately 70% of global no/low-alcohol volumes, grew by +5% in volume in 2023, and the market is now worth over $13B . The no/low alcohol category is forecast to grow at a volume CAGR of +6% between 2023 and 2027. CMND +11.
75% premarket to $1.14. More on Clearmind Medicine Inc.
Clearmind gains on exclusive global rights to psychedelic compounds for PTSD treatment Financial information for Clearmind Medicine Inc..
